Immunome Statistics
Total Valuation
Immunome has a market cap or net worth of $694.36 million. The enterprise value is $380.95 million.
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunome has 87.01 million shares outstanding. The number of shares has increased by 121.01% in one year.
| Current Share Class | 87.01M |
| Shares Outstanding | 87.01M |
| Shares Change (YoY) | +121.01% |
| Shares Change (QoQ) | +26.37% |
| Owned by Insiders (%) | 3.47% |
| Owned by Institutions (%) | 64.47% |
| Float | 69.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.62 |
| Forward PS | n/a |
| PB Ratio | 2.25 |
| P/TBV Ratio | 2.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 34.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.49
| Current Ratio | 10.49 |
| Quick Ratio | 10.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.21% and return on invested capital (ROIC) is -37.38%.
| Return on Equity (ROE) | -69.21% |
| Return on Assets (ROA) | -33.54% |
| Return on Invested Capital (ROIC) | -37.38% |
| Return on Capital Employed (ROCE) | -56.99% |
| Revenue Per Employee | $92,695 |
| Profits Per Employee | -$1.74M |
| Employee Count | 118 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.06% in the last 52 weeks. The beta is 2.01, so Immunome's price volatility has been higher than the market average.
| Beta (5Y) | 2.01 |
| 52-Week Price Change | -48.06% |
| 50-Day Moving Average | 7.86 |
| 200-Day Moving Average | 11.22 |
| Relative Strength Index (RSI) | 51.55 |
| Average Volume (20 Days) | 1,000,346 |
Short Selling Information
The latest short interest is 13.65 million, so 15.68% of the outstanding shares have been sold short.
| Short Interest | 13.65M |
| Short Previous Month | 12.48M |
| Short % of Shares Out | 15.68% |
| Short % of Float | 19.63% |
| Short Ratio (days to cover) | 9.62 |
Income Statement
In the last 12 months, Immunome had revenue of $10.94 million and -$205.11 million in losses. Loss per share was -$3.13.
| Revenue | 10.94M |
| Gross Profit | -118.60M |
| Operating Income | -177.75M |
| Pretax Income | -232.03M |
| Net Income | -205.11M |
| EBITDA | -175.73M |
| EBIT | -177.75M |
| Loss Per Share | -$3.13 |
Full Income StatementBalance Sheet
The company has $317.32 million in cash and n/a in debt, giving a net cash position of $317.32 million or $3.65 per share.
| Cash & Cash Equivalents | 317.32M |
| Total Debt | n/a |
| Net Cash | 317.32M |
| Net Cash Per Share | $3.65 |
| Equity (Book Value) | 307.13M |
| Book Value Per Share | 3.53 |
| Working Capital | 292.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$152.68 million and capital expenditures -$26.19 million, giving a free cash flow of -$178.87 million.
| Operating Cash Flow | -152.68M |
| Capital Expenditures | -26.19M |
| Free Cash Flow | -178.87M |
| FCF Per Share | -$2.06 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,625.04% |
| Pretax Margin | -1,875.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |